Pure Global
NCT05885373

A Clinical Study to Evaluate the Effect of SIM01 in Female With NAFLD

A Single-arm, Open-label Clinical Study to Evaluate the Effect of SIM01 in Female Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
GenieBiome Limited·ClinicalTrials.gov·dietary supplementRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention
SIM01
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
GenieBiome Limited
Location
Hong Kong, China
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2023
End date
Dec 31, 2023
Enrollment
40 participants
Primary outcome

Change in CAP score by fibroscan after taking SIM01 for 3 months

Summary

Non-alcoholic fatty liver disease is one of the most common chronic liver diseases worldwide.
 Available data indicates that probiotics may regulate the gut microbiota and improve liver
 function in females with non-alcoholic fatty liver disease. In this study, we aim to
 investigate if the synbiotics (prebiotics and probiotics) are efficacious subjects in liver
 function improvement in female subjects with Non-alcoholic fatty liver disease.

ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05885373
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05885373 through Pure Global AI's free database. This phase not specified trial is sponsored by GenieBiome Limited and is currently Recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.